Infant Bacterial Therapeutics AB (9IB) Income Statement

Last quarter (Q2 2025), Infant Bacterial Therapeutics AB's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q2, Infant Bacterial Therapeutics AB's net income was kr-19.17M. See Infant Bacterial Therapeutics AB’s key income statements, including revenue, expenses, profit, and income.